Is a single dose of ChAdOx1 nCoV‐19 vaccine (AZD1222) enough for people with prior SARS‐CoV‐2 infection or baseline seropositive status?. (October 2022) - Deswal, Vikas
Highlights: Better IgG responses were observed in baseline seropositive individuals. Single-dose IgG responses to AZD1222 were better in indviduals who were previously infected with COVID. One dose may be sufficient for individuals who were previously infected with COVID.